Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 681Neoplasms 593Carcinoma, Non-Small-Cell Lung 292Colorectal Neoplasms 291Prostatic Neoplasms 284Lung Neoplasms 224Melanoma 161Multiple Myeloma 151Neoplasm Metastasis 145Pancreatic Neoplasms 143Head and Neck Neoplasms 143Ovarian Neoplasms 136Carcinoma, Hepatocellular 126Leukemia, Myeloid, Acute 122Colonic Neoplasms 114Brain Neoplasms 113Squamous Cell Carcinoma of Head and Neck 111Uterine Cervical Neoplasms 109Stomach Neoplasms 104Lymphoma 101Recurrence 100Glioblastoma 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 83Lymphoma, Non-Hodgkin 82Urinary Bladder Neoplasms 78Lymphoma, Follicular 78Hematologic Neoplasms 78Glioma 75Parkinson Disease 4, Autosomal Dominant Lewy Body 73Sarcoma 72

Interventions

Lenalidomide 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Primary Cutaneous Anaplastic Large Cell × 1 year × Clear all
NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
26 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡